share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K:外國發行人報告

SEC announcement ·  01/26 12:54
Moomoo AI 已提取核心訊息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has successfully closed a registered direct offering, raising $8 million through the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS. Concurrently, the company also issued unregistered warrants to purchase an additional 10,000,000 ADSs with an exercise price of $1.00 per ADS, exercisable immediately and valid for five years. The offering was managed by H.C. Wainwright & Co., serving as the exclusive placement agent. RedHill intends to allocate the net proceeds from this offering towards general working capital, acquisitions, research and development, and other corporate purposes. The ADSs were offered under a shelf registration statement on Form F-3, declared effective by the SEC on August 9, 2021. The warrants, however, were issued in a private...Show More
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has successfully closed a registered direct offering, raising $8 million through the sale of 10,000,000 American Depositary Shares (ADSs) at a price of $0.80 per ADS. Concurrently, the company also issued unregistered warrants to purchase an additional 10,000,000 ADSs with an exercise price of $1.00 per ADS, exercisable immediately and valid for five years. The offering was managed by H.C. Wainwright & Co., serving as the exclusive placement agent. RedHill intends to allocate the net proceeds from this offering towards general working capital, acquisitions, research and development, and other corporate purposes. The ADSs were offered under a shelf registration statement on Form F-3, declared effective by the SEC on August 9, 2021. The warrants, however, were issued in a private placement and, along with the ADSs underlying the warrants, have not been registered under the Securities Act, thus limiting their sale to certain conditions. The event took place on January 26, 2024, and is part of RedHill's ongoing efforts to fund its operations and development programs, including those for gastrointestinal and infectious diseases.
專業生物製藥公司RedHill Biopharma Ltd.已成功完成註冊直接發行,通過以每股ADS0.80美元的價格出售1,000萬股美國存托股票(ADS)籌集了800萬美元。同時,該公司還發行了未註冊的認股權證,額外購買10,000,000份ADS,每份ADS的行使價爲1.00美元,可立即行使,有效期爲五年。此次發行由作爲獨家配售代理的H.C. Wainwright & Co. 管理。RedHill打算將本次發行的淨收益分配給一般營運資金、收購、研發和其他公司用途。美國證券交易委員會於2021年8月9日宣佈根據F-3表格的貨架註冊聲明提供美國存託憑證。但是,認股權證是私募發行的,與認股權證相關的ADS尚未根據《證券法》註冊,因此其出售僅限於某些條件。該活動於2024年1月26日舉行,是RedHill爲其運營和發展計劃(包括胃腸道和傳染病計劃)提供資金的持續努力的一部分。
專業生物製藥公司RedHill Biopharma Ltd.已成功完成註冊直接發行,通過以每股ADS0.80美元的價格出售1,000萬股美國存托股票(ADS)籌集了800萬美元。同時,該公司還發行了未註冊的認股權證,額外購買10,000,000份ADS,每份ADS的行使價爲1.00美元,可立即行使,有效期爲五年。此次發行由作爲獨家配售代理的H.C. Wainwright & Co. 管理。RedHill打算將本次發行的淨收益分配給一般營運資金、收購、研發和其他公司用途。美國證券交易委員會於2021年8月9日宣佈根據F-3表格的貨架註冊聲明提供美國存託憑證。但是,認股權證是私募發行的,與認股權證相關的ADS尚未根據《證券法》註冊,因此其出售僅限於某些條件。該活動於2024年1月26日舉行,是RedHill爲其運營和發展計劃(包括胃腸道和傳染病計劃)提供資金的持續努力的一部分。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息